Search research articles
Contact Us
Filters
Showing results (581-590 of 692) with videos related to
Page
of 70
Sort By:
JAMA Network Open
|
November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
Pasi A Jänne, David Planchard, Koichi Goto, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 20, 2019
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
B C M Hermans, J L Derks, E Thunnissen, et al.
The New England Journal of Medicine
|
April 28, 2025
Zongertinib in Previously Treated <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
John V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.
Cell Reports
|
April 2, 2014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
Chong Sun, Sebastijan Hobor, Andrea Bertotti, et al.
The Lancet. Oncology
|
March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Egbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
The Lancet. Oncology
|
April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard, Tae Min Kim, Julien Mazieres, et al.
The New England Journal of Medicine
|
September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
Bob T Li, Egbert F Smit, Yasushi Goto, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 25, 2012
Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern? Results of a Dutch multicentre study (MULTISENT)
O R Brouwer, L Vermeeren, I M C van der Ploeg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Page
of 70
Search research articles
Search
Showing results (581-590 of 692) with videos related to
Sort By:
Page
of 70
JAMA Network Open
|
November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
Pasi A Jänne, David Planchard, Koichi Goto, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 20, 2019
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
B C M Hermans, J L Derks, E Thunnissen, et al.
The New England Journal of Medicine
|
April 28, 2025
Zongertinib in Previously Treated <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
John V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.
Cell Reports
|
April 2, 2014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
Chong Sun, Sebastijan Hobor, Andrea Bertotti, et al.
The Lancet. Oncology
|
March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Egbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
The Lancet. Oncology
|
April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard, Tae Min Kim, Julien Mazieres, et al.
The New England Journal of Medicine
|
September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
Bob T Li, Egbert F Smit, Yasushi Goto, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 25, 2012
Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern? Results of a Dutch multicentre study (MULTISENT)
O R Brouwer, L Vermeeren, I M C van der Ploeg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Page
of 70